| Literature DB >> 34956108 |
Dingle Yu1,2, Yunmei Liang3, Qinghua Lu1,2, Qing Meng2, Wenjian Wang2, Lu Huang2, Yanmin Bao2, Ruizhen Zhao2, Yunsheng Chen2, Yuejie Zheng2, Yonghong Yang1,2.
Abstract
Streptococcus pyogenes is a bacterial pathogen that causes a wide spectrum of clinical diseases exclusively in humans. The distribution of emm type, antibiotic resistance and virulence gene expression for S. pyogenes varies temporally and geographically, resulting in distinct disease spectra. In this study, we analyzed antibiotic resistance and resistance gene expression patterns among S. pyogenes isolates from pediatric patients in China and investigated the relationship between virulence gene expression, emm type, and disease categories. Forty-two representative emm1.0 and emm12.0 strains (n = 20 and n = 22, respectively) isolated from patients with scarlet fever or obstructive sleep apnea-hypopnea syndrome were subjected to whole-genome sequencing and phylogenetic analysis. These strains were further analyzed for susceptibility to vancomycin. We found a high rate and degree of resistance to macrolides and tetracycline in these strains, which mainly expressed ermB and tetM. The disease category correlated with emm type but not superantigens. The distribution of vanuG and virulence genes were associated with emm type. Previously reported important prophages, such as φHKU16.vir, φHKU488.vir, Φ5005.1, Φ5005.2, and Φ5005.3 encoding streptococcal toxin, and integrative conjugative elements (ICEs) such as ICE-emm12 and ICE-HKU397 encoding macrolide and tetracycline resistance were found present amongst emm1 or emm12 clones from Shenzhen, China.Entities:
Keywords: China; Streptococcus pyogenes; antibiotic resistance; child; disease; emm type; superantigen
Year: 2021 PMID: 34956108 PMCID: PMC8696671 DOI: 10.3389/fmicb.2021.722225
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Susceptibility of S. pyogenes strains (N = 342) to antimicrobial agents.
| Antibiotic | R% (N) | I% (N) | S% (N) | (μg/mL) | |||
|
| |||||||
| Breakpoint | MIC50 | MIC90 | MIC range | ||||
| Penicillin | 0 | 0 | 100 (342) | S ≤ 0.125 | 0.004 | 0.008 | 0.001–0.03 |
| Azithromycin | 91.5 (313) | 0 | 8.5 (29) | S ≤ 0.5 R ≥ 2 | >256 | >256 | 0.015–512 |
| Erythromycin | 91.2 (312) | 0 | 8.8 (30) | S ≤ 0.25 R ≥ 1 | >256 | >256 | 0.0625–512 |
| Clarithromycin | 90.6 (310) | 0.9 (3) | 8.5 (29) | S ≤ 0.25 R ≥ 1 | >256 | >256 | 0.0375–512 |
| Clindamycin | 90.6 (310) | 0 | 9.4 (32) | S ≤ 0.25 R ≥ 1 | 128 | 256 | 0.015–512 |
| Tetracycline | 86.5 (296) | 0 | 13.5 (46) | S ≤ 2 R ≥ 8 | 64 | 64 | 0.125–64 |
| Levofloxacin | 0 | 1.5 (5) | 98.5 (337) | S ≤ 2 R ≥ 8 | 1 | 2 | 0.25–4 |
| Chloramphenicol | 0 | 0 | 100 (342) | S ≤ 4 R ≥ 16 | 2 | 4 | 1–4 |
S, Susceptible; I, Intermediate; R, Resistant.
FIGURE 1Distribution of Streptococcus pyogenes emm genotypes in isolates collected from pediatric patients in China from 2016 to 2018.
FIGURE 2Distribution of Streptococcus pyogenes emm types in isolates from children with different diseases.
Relationship between emm types of S. pyogenes and disease categories.
| Disease | No. of cases |
| |||||||||
| Arthritis | 5 | 2 | 3 | 0◎ | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bronchitis | 15 | 7 | 8 | 0*※ | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| HSP | 10 | 3 | 6 | 0¥* | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Impetigo | 12 | 5 | 7 | 0¤° | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| OSAS | 48 | 9 | 33◎ | 0©ᵿ | 1 | 1 | 2 | 0 | 0 | 1 | 1 |
| Pharyngeal tonsillitis | 29 | 10 | 16* | 0 ® ø | 0 | 0 | 1 | 0 | 0 | 1 | 1 |
| Pneumonia | 16 | 6 | 9 | 0ע | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Scarlet fever | 175 | 54 | 107※ | 0 | 1 | 6 | 5 | 1 | 0 | 1 | 0 |
| Sepsis | 8 | 2 | 5 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Soft tissue infection | 15 | 5 | 2◎*※ | 2**°¢øᵿ | 0 | 1 | 2 | 1 | 1 | 1 | 0 |
| Vulvitis | 3 | 0 | 1 | 1◎※$¥§¤©®◊ | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| IM | 2 | 0 | 2 | 0§ | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lymphadenitis | 2 | 1 | 1 | 0$ | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tympanitis | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Kawasaki disease | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Independent-samples | 0.615 | <0.001 | <0.001 | 1.000 | 0.858 | 0.438 | 0.925 | 0.083 | 0.986 | 0.915 | |
| Kruskal-Wallis test | NA | <0.05/105 | <0.05/105 | NA | NA | NA | NA | NA | NA | NA |
Data represent number of cases. OSAS, obstructive sleep apnea hypopnea syndrome; HSP, Henoch–Schöenlein Purpura; IM, infectious mononucleosis. ◎, *, ※, $, ¥, §, Ó, Ò, ◊, *, °, ¤, ¢, ø, and ᵿ, and ᵿ indicate that the distribution of disease categories for specific emm types was significantly different after Bonferroni correction (P
Distribution of sAgs in S. pyogenes strains according to emm types.
| No. of strains |
|
|
|
|
|
|
|
|
|
|
|
|
| |
| 105 | 93◎*※$* | 104 | 104 | 102 | 94 | 4◎ * | 4◎ * ※ | 98◎*※$*°¤oe | 2 | 1 | 2 | 104 | 104 | |
| 3 | 0◎ | 3 | 3 | 3 | 3 | 1 | 1 | 0◎ | 2 | 2 | 2 | 1 | 1 | |
| 2 | 2Δ | 2 | 0 | 2 | 0 | 0※ | 0 | 0* | 2 | 0 | 2 | 0 | 2 | |
| 8 | 2*œ | 8 | 8 | 7 | 2 | 0$ | 0$ | 0※ | 2 | 4 | 2 | 6 | 7 | |
| 14 | 122¥ | 14 | 14 | 14 | 9 | 1* | 1¥ | 1$ | 12 | 2 | 12 | 4 | 14 | |
| 201 | 5※Δ¥°oe | 199 | 199 | 198 | 176 | 171◎※$*°oe | 169◎$¥Δ | 6⁎ | 3 | 7 | 2 | 198 | 199 | |
| 2 | 1° | 2 | 2 | 2 | 2 | 0° | 0 | 0° | 0 | 0 | 0 | 2 | 2 | |
| 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1*Δ | 1 | 0 | 0 | 0 | 0 | 1 | |
| 4 | 1$ | 4 | 3 | 4 | 4 | 2* | 3※ | 0œ | 3 | 2 | 3 | 1 | 4 | |
| 2 | 0* | 2 | 1 | 2 | 2 | 0œ | 0 | 0¤ | 0 | 0 | 0 | 1 | 2 | |
| n (%) | N = 342 | 33.9 | 99.1 | 98.0 | 98.0 | 85.7 | 52.3 | 52.3 | 31.0 | 7.6 | 5.3 | 7.3 | 92.4 | 98.2 |
| Mann-Whitney U test | U | 1935.00 | 504.000 | 955.000 | 944.500 | 6715.50 | 4322.50 | 4114.00 | 1382.50 | 3637.50 | 2719.00 | 3430.50 | 3888.00 | 826.50 |
| Z | −14.728 | −0.030 | −0.959 | −1.005 | −0.823 | −12.828 | −13.088 | −15.013 | −1.108 | −0.551 | −1.276 | −0.179 | −0.863 | |
|
| <0.001 | 0.976 | 0.338 | 0.315 | 0.411 | <0.001 | <0.001 | <0.001 | 0.268 | 0.582 | 0.202 | 0.858 | 0.388 |
◎, *, ※, $, ¥, *, D, oe, °, and ¤ indicate a statistically significant difference after Bonferroni correction (P
Distribution of sAgs in S. pyogenes strains isolated from children with different diseases.
| Disease | No. of cases |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Arthritis | 5 | 2 | 5 | 5 | 5 | 5 | 3 | 3 | 2 | 0 | 0 | 0 | 5 | 5 |
| Bronchitis | 15 | 8 | 15 | 15 | 15 | 15 | 6 | 6 | 7 | 2 | 3 | 2 | 13 | 14 |
| Henoch–Schöenlein purpura | 10 | 4 | 10 | 9 | 9 | 7 | 4 | 4 | 3 | 1 | 0 | 1 | 9 | 10 |
| Impetigo | 12 | 5 | 11 | 12 | 12 | 9 | 6 | 6 | 5 | 0 | 0 | 0 | 12 | 12 |
| OSAS | 48 | 11 | 48 | 45 | 48 | 41 | 30 | 29 | 9 | 4 | 6 | 4 | 43 | 48 |
| Pharyngeal tonsillitis | 29 | 11 | 29 | 29 | 27 | 26 | 15 | 15 | 12 | 2 | 1 | 2 | 26 | 29 |
| Pneumonia | 16 | 6 | 16 | 16 | 16 | 12 | 8 | 9 | 5 | 1 | 0 | 1 | 15 | 16 |
| Scarlet fever | 175 | 54 | 174 | 173 | 172 | 148 | 95 | 94 | 52 | 8 | 5 | 8 | 168 | 172 |
| Sepsis | 8 | 3 | 8 | 8 | 8 | 7 | 5 | 5 | 2 | 1 | 1 | 1 | 8 | 8 |
| Soft tissue infection | 15 | 9 | 15 | 14 | 15 | 14 | 2 | 3 | 7 | 5 | 2 | 5 | 9 | 13 |
| Vulvitis | 3 | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 0 | 1 | 0 | 1 | 3 | 3 |
| Infectious mononucleosis | 2 | 0 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 2 | 2 |
| Lymphadenitis | 2 | 1 | 2 | 2 | 2 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 2 |
| Tympanitis | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
| Kawasaki disease | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 |
| Mann-Whitney | U | 13020.0 | 422.5 | 969.0 | 676.5 | 6913.0 | 13983.5 | 14147.5 | 12369.5 | 3509.0 | 2453.5 | 3531.5 | 3906.5 | 703.0 |
| Z | −0.109 | −0.543 | −0.846 | −0.817 | −0.446 | −0.713 | −0.520 | −0.176 | −1.331 | −1.220 | −0.975 | −0.127 | −1.368 | |
|
| 0.913 | 0.596 | 0.414 | 0.423 | 0.657 | 0.476 | 0.603 | 0.860 | 0.184 | 0.224 | 0.332 | 0.900 | 0.186 |
OSAS, obstructive sleep apnea hypopnea syndrome.
FIGURE 3Superantigen-encoding gene expression profiles in emm1.0 and emm12.0 types. Profile A: speA–, speB+, speC+, speF+, speG+, speH+, speI+, speJ–, speL–, speM–, ssa+, smeZ+, speK–. Profile B: speA+, speB+, speC+, speF+, speG+, speH–, speI–, speJ+, speL–, speM–, ssa+, smeZ+, speK–. Profile C: speA–, speB+, speC+, speF+, speG+, speH–, speI–, speJ–, speL–, speM–, ssa+, smeZ+, speK–. Profile D: speA–, speB+, speC+, speF+, speG–, speH+, speI+, speJ–, speL–, speM–, ssa+, smeZ+, speK–. Profile E: speA+, speB+, speC+, speF+, speG–, speH–, speI–, speJ+, speL–, speM–, ssa+, smeZ+, speK–.
FIGURE 4Phylogenetic relationship of selective emm1 and emm12 strains using whole genome core-gene SNPs (A,C) and their antimicrobial drug resistance gene and virulence factor variation profiles (b,d). References indicate S. pyogenes strain MGAS5005 (Genbank accession CP000017.2) and S. pyogenes strain TJ11-001 (CP028148.1), respectively (B,C). The S. pyogenes strain Bra048, assembly accession GCA_900984775, is also included in the phylogeny of emm1 for reference. Strains containing 2 copies (emm1) and 3 copies (emm12), rather than the majority 4 copies, formed clusters and are indicated in bold font. The numbers in cells (B,D) indicate gene copy numbers.